• 1
    Schimpff S, Satterlee W, Young V, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N. Engl. J. Med. 1971; 284: 10615.
  • 2
    Bertuch A, Strother D. Fever in children with chemotherapy-induced neutropenia. Revised In: UpToDate [Internet]. 2009. [accessed 11 March 2011].
  • 3
    Buchanan GR. Approach to treatment of the febrile cancer patient with low-risk neutropenia. Hematol. Oncol. Clin. North Am. 1993; 7: 91935.
  • 4
    Shenep JL. Outpatient management of the neutropenic child with unexplained fever. Semin. Pediatr. Infect. Dis. 2000; 11: 10512.
  • 5
    Klaassen RJ, Goodman TR, Doyle JJ. ‘Low-Risk’ prediction rule for pediatric oncology patients presenting with fever and neutropenia. J. Clin. Oncol. 2000; 18: 101219.
  • 6
    Cornely OA, Wicke T, Seifert H et al. Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. Int. J. Hematol. 2004; 79: 748.
  • 7
    Flaherty JP, Waitley D, Edlin B et al. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am. J. Med. 1989; 87: 278S82S.
  • 8
    Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N. Engl. J. Med. 1999; 341: 30511.
  • 9
    Giamarellou H, Bassaris HP, Petrikkos G et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob. Agents Chemother. 2000; 44: 326471.
  • 10
    Hidalgo M, Hornedo J, Lumbreras C et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999; 85: 2139.
  • 11
    Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support. Care Cancer 2008; 16: 48591.
  • 12
    Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br. J. Cancer 2003; 89: 439.
  • 13
    Kern W, Cometta A, de Bock R, Langnaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N. Engl. J. Med. 1999; 341: 3128.
  • 14
    Niho S, Ohe Y, Goto K et al. Randomized trial of oral versus intravenous antibiotics in low-risk febrile neutropenic patients with lung cancer. Jpn. J. Clin. Oncol. 2004; 34: 6973.
  • 15
    Rubenstein EB, Rolston K, Benjamin RS et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71: 36406.
  • 16
    Sebban C, Dussart S, Fuhrmann C et al. Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support. Care Cancer 2008; 16: 101723.
  • 17
    Vidal L, Paul M, Ben dor I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J. Antimicrob. Chemother. 2004; 54: 2937.
  • 18
    Vidal L, Paul M, Ben-Dor I, Pokroy E, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst. Rev. 2004; CD003992.
  • 19
    Mullen CA, Petropoulos D, Roberts WM et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86: 12634.
  • 20
    DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp. Clin. Trials 2007; 28: 10514.
  • 21
    Minotti V, Gentile G, Bucaneve G et al. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 1999; 7: 1349.
  • 22
    Petrilli AS, Dantas LS, Campos MC, Tanaka C, Ginani VC, Seber A. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. Med. Pediatr. Oncol. 2000; 34: 8791.
  • 23
    Paganini HR, Sarkis CM, De Martino MG et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 2000; 88: 284852.
  • 24
    Shenep JL, Flynn PM, Baker DK et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. Clin. Infect. Dis. 2001; 32: 3643.
  • 25
    Cagol AR, De Castro CG Jr, Martins MC et al. Oral vs. intravenous empirical antimicrobial therapy in febrile neutropenic patients receiving childhood cancer chemotherapy. J. Pediatr. (Rio. J). 2009; 85: 5315.
  • 26
    Gupta A, Swaroop C, Agarwala S, Pandey RM, Bakhshi S. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J. Pediatr. Hematol. Oncol. 2009; 31: 63541.
  • 27
    Leese B. The costs of treating febrile neutropenia in six U.K. hospitals. Eur. J. Cancer 1993; 29: S1518.
  • 28
    Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J. Clin. Oncol. 1994; 12: 10714.
  • 29
    Aquino VM, Herrera L, Sandler ES, Buchanan GR. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 2000; 88: 17104.
  • 30
    Bally F, Marchetti O, Cometta A. [Febrile neutropenia]. Rev Prat. 2003; 53: 21017.
  • 31
    Bash RO, Katz JA, Cash JV, Buchanan GR. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994; 74: 18996.
  • 32
    Batlle M, Lloveras N. [Management of low-risk febrile patients with neutropenia]. Enferm. Infecc. Microbiol. Clin. 2005; 23 (Suppl 5): 304.
  • 33
    Chan CC, Oppenheim BA, Anderson H, Swindell R, Scarffe JH. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob. Agents Chemother. 1989; 33: 8791.
  • 34
    Cometta A, Kern W, International antimicrobial therapy cooperative group de l E. [Treatment with oral antibiotics of febrile neutropenia in onco-haematology. The experience of the EORTC antimicrobial group]. Presse Med. 2004; 33: 3279.
  • 35
    Cornelissen JJ, Rozenberg-Arska M, Dekker AW. Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clin. Infect Dis. 1995; 21: 13002.
  • 36
    Davis DD, Raebel MA. Ambulatory management of chemotherapy-induced fever and neutropenia in adult cancer patients. Annals of Pharmacotherapy 1998; 32: 131723.
  • 37
    Dommett R, Geary J, Freeman S et al. Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting. Eur. J. Cancer 2009; 45: 28439.
  • 38
    Escalante CP, Rubenstein EB, Rolston KV. Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Cancer Invest. 1997; 15: 23742.
  • 39
    Escalante CP, Weiser MA, Manzullo E et al. Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients. Support Care Cancer 2004; 12: 65762.
  • 40
    Friefeld A, Pizzo PA. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatr. Infect. Dis. J. 1997; 16: 1406.
  • 41
    Gilbert C, Meisenberg B, Vredenburgh J et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. Journal of Clinical Oncology 1994; 12: 100511.
  • 42
    Hodgson-Viden H, Grundy PE, Robinson JL. Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr. 2005; 5: 10.
  • 43
    Horowitz HW, Holmgren D, Seiter K. Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leuk Lymphoma. 1996; 23: 15963.
  • 44
    Johnson PR, Liu Yin JA, Tooth JA. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. J. Antimicrob. Chemother 1992; 30: 20314.
  • 45
    Karthaus M, Carratala J, Jurgens H, Ganser A. New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia? Chemotherapy 1998; 44: 42735.
  • 46
    Karthaus M, Meran JG, Geissler RG, Bohme A, Jurgens H, Ganser A. [Possibilities and limits of ambulatory supportive measures in oncology exemplified by antibiotic therapy of febrile neutropenia]. Wien Med. Wochenschr. 1998; 148: 42732.
  • 47
    Karthaus M, Cornely OA, Sudhoff T, Meran J. [Antimicrobial therapy of febrile neutropenia–current developments]. Wien Med. Wochenschr. 2001; 151: 6672.
  • 48
    Kern WV. Risk assessment and risk-based therapeutic strategies in febrile neutropenia. Curr. Opin. Infect. Dis. 2001; 14: 41522.
  • 49
    Klaassen RJ, Allen U, Doyle JJ. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia. J. Pediatr. Hematol. Oncol. 2000; 22: 40511.
  • 50
    Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin. Infect Dis. 2004; 39 (Suppl 1): S327.
  • 51
    Klastersky J, Paesmans M, Institut Jules Bordet CdTdlULdB. Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Support Care Cancer 2007; 15: 47782.
  • 52
    Koh A, Pizzo PA. Empirical oral antibiotic therapy for low risk febrile cancer patients with neutropenia. Cancer Invest. 2002; 20: 42033.
  • 53
    Kridel R, Van Delden C, Calandra T, Marchetti O. [Empirical antibiotic therapy for febrile neutropenia]. Rev. Med. Suisse. 2008; 4: 914.
  • 54
    Lau RC, Doyle JJ, Freedman MH, King SM, Richardson SE. Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatr. Hematol. Oncol. 1994; 11: 41721.
  • 55
    Leverger G. [Outpatient antibiotherapy in children with neutropenia and fever. A review of the literature.]. Presse Med. 2004; 33: 3307.
  • 56
    Marra CA, Frighetto L, Quaia CB et al. A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis. Pharmacotherapy. 2000; 20: 93140.
  • 57
    Mullen CA. Which children with fever and neutropenia can be safely treated as outpatients? Br. J. Haematol. 2001; 112: 8327.
  • 58
    Paganini H, Rodriguez-Brieshcke T, Zubizarreta P et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 2001; 91: 15637.
  • 59
    Park JR, Coughlin J, Hawkins D, Friedman DL, Burns JL, Pendergrass T. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. Med. Pediatr. Oncol. 2003; 40: 938.
  • 60
    Roguin A, Kasis I, Ben-Arush MW, Sharon R, Berant M. Fever and neutropenia in children with malignant disease. Pediatric Hematology and Oncology. 1996; 13: 50310.
  • 61
    Rubenstein EB, Rolston K. Outpatient management of febrile episodes in neutropenic cancer patients. Support Care Cancer 1994; 2: 36973.
  • 62
    Sahu S, Bapna A, Pai SK, Nair CN, Kurkure PA, Advani SH. Outpatient antimicrobial protocol for febrile neutropenia: a nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents. Pediatr. Hematol. Oncol. 1997; 14: 20511.
  • 63
    Santos-Machado TM, De Aquino MZ, Almeida MTA et al. Short-term intravenous antibiotic therapy and early discharge of febrile neutropenic patients. International Journal of Pediatric Hematology/Oncology 1999; 6: 338.
  • 64
    Schaad UB, Pfenninger J, Wedgewood-Krucko J. Sequential intravenous-oral amoxycillin/clavulanate (Augmentin) therapy in paediatric hospital practice. J. Antimicrob. Chemother. 1987; 19: 38591.
  • 65
    Shrestha PN, Sah KP, Rana R. Emperical oral antibiotic therapy for children with low risk febrile neutropenia during cancer chemotherapy. Journal of Nepal. Paediatric Society 2009; 29: 225.
  • 66
    Timmers GJ, Simoons-Smit AM, Leidekker ME, Janssen JJWM, Vandenbroucke-Grauls CMJE, Huijgens PC. Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies. Clin. Microbiol. Infect. 2007; 13: 497503.
  • 67
    Wacker P, Halperin DS, Wyss M, Humbert J. Early hospital discharge of children with fever and neutropenia: A prospective study. J. Pediatr. Hematol. Oncol. 1997; 19: 20811.